https://doi.org/10.22037/ijpr.2016.1943

Creatine Revealed Anticonvulsant Properties on Chemically and Electrically Induced Seizures in Mice

authors:

avatar Hamed Shafaroodi a , b , avatar Farnaz Shahbek a , avatar Mehrdad Faizi c , avatar Farzad Ebrahimi d , avatar Leila Moezi e , *

Department of Pharmacology and Toxicology, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran.
Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Department of Pharmacology and Toxicology, Faculty of Pharmacy , Shahid Beheshti University of Medical Sciences , Tehran , Iran.
Department of Anesthesiology, Advocate Illinois Masonic Medical Center, University of Illinois, Chicago, IL, USA.
Department of Pharmacology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Iranian Journal of Pharmaceutical Research : IJPR: Vol.15, issue 4; 843-850
article type: Original Article
received: April , 2016
accepted: September , 2016

How To Cite Shafaroodi H, Shahbek F, Faizi M, Ebrahimi F, Moezi L. Creatine Revealed Anticonvulsant Properties on Chemically and Electrically Induced Seizures in Mice. Iran J Pharm Res. 2016;15(4):e125214. https://doi.org/10.22037/ijpr.2016.1943.

Abstract

Creatine exerts beneficial effects on a variety of pathologies in which energy metabolism and oxidative stress play an etiological role. Creatine supplements have shown beneficial effects on neurological disorders including Parkinson׳s disease, Huntington›s disease, amyotrophic lateral sclerosis, as well as Alzheimer›s disease and stroke. However, the potential benefits of creatine for patients with convulsive disorders remain poorly defined. While some authors did not suggest any anti- or pro-convulsant roles for creatine treatment, others suggest that creatine may be an anticonvulsant agent. In this study, we investigated the effects of creatine on seizures in mice.
Three models were used to explore the role of creatine on seizures in mice including intravenous pentylenetetrazole (PTZ), intraperitoneal PTZ, and electroshock models.
Acute creatine treatment (10, 20, 40 and 80 mg/Kg) significantly increased the clonic seizure threshold in the intravenous PTZ model. Sub-chronic administration of creatine (10 and 20 mg/Kg) revealed a significant anticonvulsant effect in intravenous PTZ model. Acute creatine administration (10, 20 and 40 mg/Kg) significantly decreased the frequency of clonic seizures in the intraperitoneal PTZ model. Besides, acute creatine (40 and 80 mg/Kg) decreased the incidence of tonic seizures after electroshock.
In conclusion, creatine exerts anticonvulsant effects in three seizure models; therefore, it may act as a potential drug to help patients with convulsions. However, further investigations should be done to clarify these results more.

Introduction

According to a paper using a meta-analytic approach, more than 65 million people worldwide suffer from epileptic disorders (1). The rate of epilepsy in developed countries is approximately 50 per 100,000 individuals per year with the highest rates in the neonatal periods and in the elderly (2). While single-drug therapy provides optimal seizure control in about 80% of all patients, seizure activity remains uncontrolled in a significant number of individuals, even with the use of combination therapy (3). Therefore, further investigations to find alternative therapies for epilepsy are necessary.

Creatine (N-[aminoiminomethyl]- N-methyl glycine, Cr) is a guanidine compound synthesized from glycine, arginine, and S-adenosylmethionine in the kidney, liver, pancreas, and brain, but it can also be obtained through diet, especially from meat and fish (4, 5). Its administration increases intracellular stores of both Cr and its phosphorylated form, phosphorylcreatine (PCr), in several tissues including skeletal muscles and the brain (6, 7). Cr is a popular dietary supplement that is used by athletes in order to increase anabolic hormonal response, muscle mass, strength, and sport performance (8).

However, new uses for Cr have emerged suggesting that it may be important in preventing or delaying the onset of neurodegenerative diseases associated with aging. Cr has been shown to have antioxidant properties, reduce mental fatigue, protect the brain from neurotoxicity, and improve neurological disorders like depression and bipolar disorder. Therefore, the use of oral Cr supplementation is now being extended in medical fields in order to prevent or treat a number of age-related diseases, such as Parkinson›s disease,Huntington›s disease, amyotrophic lateral sclerosis, long-term memory impairments associated with progression of Alzheimer׳s disease and stroke (9-11).

Although there is increasing evidence supporting the use of Cr in treatment of several neurological diseases, the potential benefits of this compound for patients with convulsive disorders have not been clearly defined. While some authors did not suggest any anti- or pro-convulsant roles for Cr treatment (8i12), others suggest that Cr may be an anticonvulsant agent (3, 13, 14). Therefore, in the current study we studied the effects of Cr in modulating seizure propensity using different experimental models including intravenous pentylenetetrazole (PTZ), intraperitoneal PTZ,and maximal electroshock models.

Experimental

Chemicals

PTZ and Cr were purchased from Sigma-Aldrich (USA) and both drugs were dissolved in physiological saline solution to a concentration at which the required doses were administered in a volume of 10 mL/Kg. Cr was administered intraperitoneally. PTZ was injected intraperitoneally or intravenously depending on model of induced seizure.

Animals

Male NMRI albino mice weighing 20-30 g were housed 5-6 per cage in a room with a controlled temperature of 22 ± 1 °C. The room had an alternating 12 h light-dark cycle starting at 7:00 A.M. Animals had free access to food and water and were group housed during testing procedures. All procedures were approved and carried out in accordance with institutional guidelines for laboratory animal care and use. Each mouse was used only once and each treatment group consisted of 8-10 animals, which were randomly selected. All animals were acclimated at least 3 days before experiments. All behavioral experiments were conducted during the period between 10:00 and 14:00 hours. All the animals were euthanized immediately after the experiment.

Behavioral seizure evaluation

Intraperitoneal PTZ-induced seizure

Generalized tonic-clonic seizure induced by intraperitoneal pentylenetetrazole is a distinct model related to generalized tonic-clonic seizures (15). In this model, pentylenetetrazole (85 mg/Kg, CD97 for generalized tonic-clonic seizures in the current experiment) was administered with a single intraperitoneal injection (16, 17). Immediately after injection of PTZ, animals were transferred to an open field (50 cm in diameter) and monitored for the appearance of convulsion or death in 30 min. Following the administration of 85 mg/Kg of PTZ, time latencies and incidences for the generalized clonus were reported. Generalized clonus is described as the involvement of all four limbs and tail rearing, wild running and jumping, sudden loss of upright posture and autonomic signs such as hyper-salivation and defecation. The incidence of death was also recorded.

Intravenous PTZ-induced seizure

In addition to intraperitoneal PTZ-induced seizure model, drug effects on clonic-tonic seizures can be studied by using intravenous PTZ-induced seizure model which induces tonic seizures in all animals. Compared to the intraperitoneal injection of a fixed dose of PTZ in a group of animals, PTZ can be used by intravenous infusion to determine the individual seizure threshold of each subject. This model may have advantages, because thresholds for clonic and tonic seizures can be separately determined in the same animals, thus providing a sensitive test system for separate evaluation of drug effects on different seizure types in a small number of rodents (15, 18). In this study, PTZ-induced clonic seizure threshold was determined by inserting a 30 gauge dental needle into the tail vein of the mouse and securing the needle with a narrow piece of adhesive tape (16). PTZ solution (0.5%) was infused at a constant rate of 0.5 mL/min using an infusion pump (Harvard, USA) to unrestraine freely moving animals. Infusion was halted when forelimb clonus followed by full clonus of the body was observed. Minimal dose of PTZ (mg/Kg of mice weight) needed to induce clonic seizure was considered as an index of seizure threshold.

Maximal electroshock test

To examine the anticonvulsant effects of Cr, an electroconvulsive therapy apparatus (Model 7800, UgoBasile, Camerio, Italy) was also used. In maximal electroshock (MES) test, passing alternating current (50 Hz, 35 mA and 0.2 s) via ear electrodes causes tonic extensions of the hind limbs of mice. In order to improve electrode contact, the electrodes were moistened with normal saline before being attached to the ears of mice (19, 20). Data were expressed as percent protection, which is the percentage of animals in each group that did not exhibit hind-limb extension after electroshock.

Treatment

Three methods of intraperitoneal and intravenous administration of PTZ and electroshock were used to assess the seizure susceptibility.

Intravenous PTZ experiments: In experiment 1, to find out the best time for anticonvulsant effect of the drug, Cr (20 mg/Kg) was administered intraperitoneally, 30, 60 and 120 min prior to PTZ to distinct groups of mice. In experiment 2, Cr (5, 10, 20, 40 and 80 mg/Kg) was administered intraperitoneally in different groups of male mice 60 min before intravenous PTZ. This time point was selected according to experiment 1. In experiment 3, which we wanted to find the sub-chronic effects of Cr, the drug was administered at doses of 10 and 20 mg /Kg intraperitoneally for 5 days and intravenous PTZ experiments were done in the sixth day.

Intraperitoneal PTZ experiments: Cr (10, 20 and 40 mg/Kg) was administered intraperitoneally in different groups of male mice 60 min before intraperitoneal PTZ.

Electroshock experiments: Cr (20, 40 and 80 mg/Kg) was injected intraperitoneally in different groups of mice 60 min before electroshock.

Statistical analysis

Data are expressed as means ± SEM of 8-10 mice and analyzed using the SPSS statistical software package (Version 18.0). One-way analyses of variance (ANOVA) and post hoc Tukey’s tests were used to analyze the data. In order to determine the protective effects against tonic seizure and death, Fisher’s exact test was used. P<0.05 was considered statistically significant.

Results

Effect of acute and sub-chronic creatine administration on clonic seizure threshold in intravenous PTZ model

Figure 1a. shows anticonvulsant effect of Cr (20 mg/Kg) at different times after injections. One-way ANOVA revealed a significant effect of Cr in different times (F[3,23] = 19.577, P < 0.001). Post hoc analysis indicated that Cr exerted an anticonvulsant effect 30 min after administration (P < 0.05). This effect increased thereafter at 60 min after Cr administration, which was its maximal effect (P < 0.01).Therefore, we administered Cr, 60 min before seizure induction in the next experiments.

Figure 1b. shows the effect of acute intraperitoneal administration of different doses of Cr (5, 10, 20, 40, and 80 mg/Kg) on PTZ-induced clonic seizure threshold. One-way ANOVA revealed a significant effect of treatment (F[5,37] = 9.897, P < 0.001). Post hoc analysis indicated a significant anticonvulsant effect of acute Cr treatment at doses of 10, 20, 40, and 80 mg/Kg with maximal effect at 10 and 20 mg/Kg (P < 0.001).

(a) Time course of the anticonvulsant effect of creatine (20 mg/Kg) (b) Effect of acute creatine treatment (c) Effect of sub- chronic creatine treatment on intravenous PTZ-induced seizure threshold in mice. Creatine was administered intraperitoneally. Data are means ± SEM. *P < 0.05, **P < 0.01 and ***P < 0.001 compared with the saline group. Each group consisted of eight to ten mice

(a) Time course of the anticonvulsant effect of creatine (20 mg/Kg) (b) Effect of acute creatine treatment (c) Effect of sub- chronic creatine treatment on intravenous PTZ-induced seizure threshold in mice. Creatine was administered intraperitoneally. Data are means ± SEM. *P < 0.05, **P < 0.01 and ***P < 0.001 compared with the saline group. Each group consisted of eight to ten mice

Figure 1

Effect of acute treatment with different doses of creatine on (a) clonic seizure threshold and (b) frequency of clonic seizures in intraperitoneal PTZ mode of mice. Creatine was administered intraperitoneally 60 min prior to PTZ injection. Data are expressed as mean ± S.E.M. *P < 0.05 compared to saline group. Each group consisted of eight to ten mice

Effect of acute treatment with different doses of creatine on (a) clonic seizure threshold and (b) frequency of clonic seizures in intraperitoneal PTZ mode of mice. Creatine was administered intraperitoneally 60 min prior to PTZ injection. Data are expressed as mean ± S.E.M. *P < 0.05 compared to saline group. Each group consisted of eight to ten mice

Figure 2

Table 1

Effect of acute treatment with different doses of creatine on the incidence of death in intraperitoneal PTZ-induced seizure model

GroupsMortality (%)
Vehicle (saline)83.3
Creatine (10 mg/Kg)75
Creatine (20 mg/Kg)50
Creatine (40 mg/Kg)37.5
Table 2

Effect of acute treatment with different doses of creatine on the incidence of hind-limb extension in electroshock-induced seizure model

GroupsMortality (%)
Vehicle (saline)83.3
Creatine (10 mg/Kg)75
Creatine (20 mg/Kg)50
Creatine (40 mg/Kg)37.5

Figure 1c. shows the effect of sub-chronic administration of Cr (10 and 20 mg/Kg) on intravenous PTZ-induced clonic seizure threshold. One-way ANOVA revealed a significant anticonvulsant effect of sub-chronic Cr administration at both doses [F(2, 19) = 9.22, P < 0.01].

Effect of acute administration of different doses of creatine on intraperitoneal PTZ-induced seizures

Figure 2a. illustrates the effect of acute administration of Cr (10, 20, and 40 mg/Kg) 60 min prior to intraperitoneal PTZ administration on clonic seizure latency. One-way ANOVA did not reveal a significant effect of Cr on clonic seizure latencies [F(3, 26) = 0.556, P > 0.05].

The frequency (number of clonic seizures within 30 min after PTZ administration) has been shown in Figure 2b. [F(3, 26) = 3.064, P < 0.05]. Cr (10, 20 and 40 mg/Kg) significantly decreased the frequency of clonic seizures (P < 0.05). However, it did not have any significant effect on mortality rate in all groups (Table 1).

Effect of acute administration of different doses of creatine on electroshock-induced seizures

The results of acute administration of different doses of Cr (20, 40 and 80 mg/Kg) in the electroshock-induced seizure model are shown in Table 2. Fisher’s exact test revealed a significant effect of Cr (40 and 80 mg/Kg) on the incidence of tonic seizures after electroshock (P < 0.05).

Discussion

The present work shows the anti-convulsant effect of Cr in three seizure models including intravenous PTZ, intraperitoneal PTZ, and electroshock. In addition to the pool of Cr in the muscle, high levels of Cr are found in the brain (21). Although many of the molecular mechanisms are not well understood, Cr supplementation has been proposed and/or proven partially in a variety of animal/cellular models of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s disease (22). There are some papers which showed the anti-convulsant effects of creatine. For example, it has been shown that the acute creatine administration improves mitochondrial membrane potential and protects rats against pentylenetetrazole-induced seizures (14). Another study (Magni et al., 2007) reported that creatine decreases convulsions and neurochemical alterations induced by glutaric acid in rats (13). On the other hand, some authors did not show any effect of Cr on convulsion. For example, Mikati et al. (2004) showed that creatine supplementation cannot prevent spontaneous recurrent seizures (12) and Saraiva et al. (2012) indicated that creatine did not protect against seizure susceptibility after severe traumatic brain injury (23).

Induction of seizures by intravenous infusion of PTZ is a standard experimental model of clinical myoclonic seizures that has both face and construct validity (15, 24). This model has proven to be more sensitive than intraperitoneal PTZ administration and allows better detection of modulatory effects on convulsive tendency (15, 25, 26). PTZ increases activity in major epileptogenic centers of the forebrain like amygdala and piriform cortex (27). Neurochemical evidence suggests that PTZ binds to the picrotoxin site of the GABA receptor complex and blocks GABA-mediated inhibition (28). In this study, we indicated a significant anticonvulsant effect of acute Cr treatment at doses of 10, 20, 40 and 80 mg/Kg with maximal effect at 10 and 20 mg/Kg in intravenous PTZ model. We also showed a significant anticonvulsant effect of sub-chronic Cr administration (10 and 20 mg/Kg, for seven days) in intravenous PTZ models. To the best of our knowledge, this study is the first study that showed the anti-convulsant effect of Cr in intravenous PTZ model. We also examined the effect of acute Cr treatment on generalized tonic–clonic seizures induced by intraperitoneal injection of high dose of PTZ. Generalized tonic-clonic seizure induced by intraperitoneal high dose of PTZ is an animal model related to grand mal seizures in humans (15, 29). In this model, PTZ (85 mg/Kg, CD97 for clonic seizures in the current experiment) was administered with a single intraperitoneal injection to evaluate the latency for the onset of clonic seizures and the incidence of tonic and death following seizures (16, 17). In intraperitoneal PTZ model we revealed that Cr at doses of 10, 20, and 40 mg/Kg/day significantly decreased the frequency of clonic seizures without any effect on clonic seizure latency and death. The anti-convulsant effects of Cr in acute treatment which shows in PTZ seizure models are in line with some previous studies (13, 14). Rambo et al., 2013 showed that acute Cr treatment prevents the increase in electroencephalographic wave amplitude typically elicited by intraperitoneal PTZ. Cr treatment also increases the latency periods of first myoclonic jerks, lengthened the latency periods of the generalized tonic–clonic seizures and reduces the time spent in the generalized tonic–clonic seizures induced by PTZ (14).

Apart from PTZ seizure models, in this study another seizure model, the maximal (tonic extension) electroshock seizure (MES) test, a model for generalized tonic-clonic (grand mal) seizures was used which is almost universally employed today in anticonvulsant screening, structure-activity research, ‘rational drug design’, and other approaches to antiepileptic drug development (30). We believe that this is the first study revealed a significant effect of Cr (40 and 80 mg/Kg) on the incidence of tonic seizures after electroshock. Based on our findings, Cr might play a role (as a drug or as a food additive) in people with seizure.

In conclusion, we showed the anti-convulsant effects of Cr in 3 animal models of seizure including intravenous PTZ, intraperitoneal PTZ, and maximal electroshock.

References

  • 1.

    Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia. 2010;51:883-90. [PubMed ID: 20067507].

  • 2.

    Banerjee PN, Filippi D, Allen Hauser W. The descriptive epidemiology of epilepsy-a review. Epilepsy Res. 2009;85:31-45. [PubMed ID: 19369037].

  • 3.

    Rambo LM, Ribeiro LR, Oliveira MS, Furian AF, Lima FD, Souza MA, Silva LF, Retamoso LT, Corte CL, Puntel GO, de Avila DS, Soares FA, Fighera MR, Mello CF, Royes LF. Additive anticonvulsant effects of creatine supplementation and physical exercise against pentylenetetrazol-induced seizures. Neurochem. Int. 2009;55:333-40. [PubMed ID: 19393274].

  • 4.

    Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol. Rev. 2000;80:1107-1213. [PubMed ID: 10893433].

  • 5.

    Braissant O, Henry H. AGAT, GAMT and SLC6A8 distribution in the central nervous system, in relation to creatine deficiency syndromes: a review. J. Inherit. Metab. Dis. 2008;31:230-9. [PubMed ID: 18392746].

  • 6.

    Ipsiroglu OS, Stromberger C, Ilas J, Hoger H, Muhl A, Stockler-Ipsiroglu S. Changes of tissue creatine concentrations upon oral supplementation of creatine-monohydrate in various animal species. Life Sci. 2001;69:1805-15. [PubMed ID: 11665842].

  • 7.

    Royes LF, Fighera MR, Furian AF, Oliveira MS, Myskiw Jde C, Fiorenza NG, Petry JC, Coelho RC, Mello CF. Effectiveness of creatine monohydrate on seizures and oxidative damage induced by methylmalonate. Pharmacol. Biochem. Behav. 2006;(83):136-44. [PubMed ID: 16469366].

  • 8.

    Eckerson JM, Stout JR, Moore GA, Stone NJ, Nishimura K, Tamura K. Effect of two and five days of creatine loading on anaerobic working capacity in women. J. Strength. Cond. Res. 2004;18:168-73. [PubMed ID: 14971965].

  • 9.

    Pastula DM, Moore DH, Bedlack RS. Creatine for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst. Rev. 2012;12. CD005225.

  • 10.

    Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang GS, Ross GW, Tilley BC, Shulman LM, Investigators N-P. Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. JAMA Neurol. 2014;71:710-6. [PubMed ID: 24711047].

  • 11.

    Smith RN, Agharkar AS, Gonzales EB. A review of creatine supplementation in age-related diseases: more than a supplement for athletes. F1000Res. 2014;3:222. [PubMed ID: 25664170].

  • 12.

    Mikati MA, Kurdit RM, Rahmeh AA, Farhat F, Abu Rialy S, Lteif L, Francis E, Geha G, Maraashli W. Effects of creatine and cyclocreatine supplementation on kainate induced injury in pre-pubescent rats. Brain Inj. 2004;18:1229-41. [PubMed ID: 15666567].

  • 13.

    Magni DV, Oliveira MS, Furian AF, Fiorenza NG, Fighera MR, Ferreira J, Mello CF, Royes LF. Creatine decreases convulsions and neurochemical alterations induced by glutaric acid in rats. Brain Res. 2007;1185:336-45. [PubMed ID: 17950259].

  • 14.

    Rambo LM, Ribeiro LR, Della-Pace ID, Stamm DN, da Rosa Gerbatin R, Prigol M, Pinton S, Nogueira CW, Furian AF, Oliveira MS, Fighera MR, Royes LF. Acute creatine administration improves mitochondrial membrane potential and protects against pentylenetetrazol-induced seizures. Amino Acids. 2013;44:857-68. [PubMed ID: 23064877].

  • 15.

    Loscher W, Honack D, Fassbender CP, Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs III Pentylenetetrazole seizure models. Epilepsy Res. 1991;8:171-89. [PubMed ID: 1907909].

  • 16.

    Loscher W, Lehmann H. L-deprenyl (selegiline) exerts anticonvulsant effects against different seizure types in mice. J. Pharmacol. Exp. Ther. 1996;277:1410-7. [PubMed ID: 8667204].

  • 17.

    Moezi L, Shafaroodi H, Hassanipour M, Fakhrzad A, Hassanpour S, Dehpour AR. Chronic administration of atorvastatin induced anti-convulsant effects in mice: the role of nitric oxide. Epilepsy Behav. 2012;23:399-404. [PubMed ID: 22405864].

  • 18.

    Loscher W, Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res. 1988;2:145-81. [PubMed ID: 3058469].

  • 19.

    Sattarinezhad E, Shafaroodi H, Sheikhnouri K, Mousavi Z, Moezi L. The effects of coenzyme Q10 on seizures in mice: the involvement of nitric oxide. Epilepsy Behav. 2014;37:36-42. [PubMed ID: 24972157].

  • 20.

    Shafaroodi H, Oveisi S, Hosseini M, Niknahad H, Moezi L. The effect of acute aripiprazole treatment on chemically and electrically induced seizures in mice: The role of nitric oxide. Epilepsy Behav. 2015;48:35-40. [PubMed ID: 26037847].

  • 21.

    Mujika I, Padilla S. Creatine supplementation as an ergogenic aid for sports performance in highly trained athletes: a critical review. Int. J. Sports Med. 1997;18:491-6. [PubMed ID: 9414070].

  • 22.

    Adhihetty PJ, Beal MF. Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. Neuromolecular Med. 2008;10:275-90. [PubMed ID: 19005780].

  • 23.

    Saraiva AL, Ferreira AP, Silva LF, Hoffmann MS, Dutra FD, Furian AF, Oliveira MS, Fighera MR, Royes LF. Creatine reduces oxidative stress markers but does not protect against seizure susceptibility after severe traumatic brain injury. Brain Res. Bull. 2012;87:180-6. [PubMed ID: 22051612].

  • 24.

    Swinyard EA, Kupferberg HJ. Antiepileptic drugs: detection, quantification, and evaluation. Fed. Proc. 1985;44:2629-33. [PubMed ID: 4007184].

  • 25.

    Ghasemi A, Saberi M, Ghasemi M, Shafaroodi H, Moezi L, Bahremand A, Montaser-Kouhsari L, Ziai P, Dehpour AR. Administration of lithium and magnesium chloride inhibited tolerance to the anticonvulsant effect of morphine on pentylenetetrazole-induced seizures in mice. Epilepsy Behav. 2010;19:568-74. [PubMed ID: 20920846].

  • 26.

    Moezi L, Shafaroodi H, Hojati A, Dehpour AR. The interaction of melatonin and agmatine on pentylenetetrazole-induced seizure threshold in mice. Epilepsy Behav. 2011;22:200-6. [PubMed ID: 21840768].

  • 27.

    Gale K. Subcortical structures and pathways involved in convulsive seizure generation. J. Clin. Neurophysiol. 1992;9:264-77. [PubMed ID: 1350593].

  • 28.

    Kaputlu I, Uzbay T. L-NAME inhibits pentylenetetrazole and strychnine-induced seizures in mice. Brain Res. 1997;753:98-101. [PubMed ID: 9125436].

  • 29.

    Kupferberg H. Animal models used in the screening of antiepileptic drugs. Epilepsia. 2001;42(Suppl 4):7-12. [PubMed ID: 11564118].

  • 30.

    Loscher W, Fassbender CP, Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs II Maximal electroshock seizure models. Epilepsy Res. 1991;8:79-94. [PubMed ID: 2065646].